Search Semax before and after and you get forum logs and stopwatch claims. The published human record is one 2020 imaging study in 52 healthy adults, and what it measured was brain connectivity.
The short answer. The only published human before-and-after for Semax is a 2020 brain scan of 52 healthy adults.
- That study measured resting-state connectivity, reporting a right-amygdala change. It did not measure focus or memory.
- Zero Western randomized controlled trials of Semax sit in PubMed.
- The strongest evidence is rat stroke gene expression work, including a reported rebalancing of 1,171 genes in 24 hours.
Semax has one published human imaging study. It scanned 52 healthy adults in 2020. The finding was a connectivity change, not a test score. Zero Western randomized trials sit in PubMed. Focus and memory claims have no controlled human data. The rest of the record is rats and test tubes.
What was actually measured in people
One human study is what the whole "before and after" idea rests on. Panikratova and colleagues scanned 52 healthy adults and published in Doklady Biological Sciences in 2020. The design was a functional connectomic one: look at resting-state brain networks before, look again after.
The reported change was in connectivity involving the right amygdala. That is the before and after. It is a map of how brain regions co-activate at rest.
Functional connectomic approach to studying Selank and Semax effects.
Panikratova et al., Doklady Biological Sciences, 2020 — paper titleRead the title again. It describes a method, not an outcome anyone can feel. A connectivity shift is a real measurement, and it is not the same thing as sharper thinking, faster recall, or a better mood. Nothing in that study turns into a photograph.
The full picture of where Semax evidence comes from sits in the Semax complete guide.
Why there is no photo and no test score
Semax is a 7 amino acid fragment of ACTH. It is a nasal peptide used in Russia for stroke. It does not change skin, muscle, or body weight. So the visual before-and-after format that sells fat-loss and repair peptides has nothing to photograph here.
What people want instead is a cognitive before and after: reaction time, working memory, exam scores. That data does not exist in controlled form.
- Zero Western randomized controlled trials. We found none in PubMed.
- No placebo-controlled cognitive trial in healthy adults that we can point you to.
- One human imaging study, in 52 people, reporting connectivity.
- No long-term safety follow-up published outside the Russian clinical setting.
This article is built from 13 published studies. One of them involved humans. That ratio is the honest answer to the query.
What the peptide is claimed to do, and what sits under each claim, is broken down in Semax benefits.
What the animal studies actually measured
The rest of the record is strong in a narrow way. It is mostly rats, mostly stroke, and mostly molecular. The outcome is usually a gene or a protein, not a behavior.
| Study | Model | What was measured |
|---|---|---|
| Filippenkov et al., 2024 | Rat experimental stroke | Brain gene expression one day after |
| Dergunova et al., 2021 | Rat reversible brain ischemia | Proinflammatory mRNA transcripts |
| Sudarkina et al., 2021 | Rat ischemia-reperfusion | Brain protein expression profile |
| Filippenkov et al., 2023 | Rat, early post-stroke period | Immune gene expression pattern |
| Inozemtseva et al., 2024 | Male rats, chronic unpredictable stress | Antidepressant-like and antistress behavior |
| Liu et al., 2025 | Female mice, spinal cord injury | Oprm1 deubiquitination, functional recovery |
| Glazova et al., 2020 | Rats, early-life fluvoxamine exposure | Behavioral and neurochemical changes |
| Svishcheva et al., 2021 | Rats, restraint stress | Large intestine tissue state |
| Elagina et al., 2020 | Rats, diabetes model | Lipid metabolism markers |
Two more papers are not in an animal at all. Sciacca and colleagues in ACS Chemical Neuroscience (2022) and Tomasello and colleagues in Bioinorganic Chemistry and Applications (2025) worked with copper, amyloid and artificial membranes. Those are chemistry results. Vyunova and colleagues (2023) looked at binding in the GABA-receptor system.
ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke.
Filippenkov et al., Biomedicines, 2024 — paper titleThat line is the high point of the Semax literature, and it is about rats and transcripts. The Kurchatov group reports a rebalancing of 1,171 stroke-disrupted genes inside 24 hours. We walk through that work in the stroke recovery research page.
Semax
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Why people still report feeling a change
Self-reports of a Semax effect are common and they arrive fast. Users often describe something within 5–20 minutes of a nasal dose. Speed feels like proof. It is not.
- No blinding. The person reporting knows what they took and what it costs.
- No baseline. Almost nobody runs a cognitive test the week before.
- Stacking. Semax is usually taken alongside caffeine, other nootropics, or a new sleep routine.
- Nasal sting is a cue. A route you can feel makes an effect easier to believe.
There is also a real mechanism story, which makes the reports harder to dismiss outright. Semax touches dopamine, serotonin, melanocortin, GABA and opioid pathways, and the proposed core is BDNF and NGF. That is covered in the ACTH and BDNF mechanism page. A plausible mechanism is a reason to run the trial. It is not the trial.
Semax has existed for about 30 years and has been an approved Russian nasal product for much of that time. A controlled cognitive trial in healthy people was always possible. It has not been published in English.
The stroke numbers people borrow
When a Semax before-and-after post cites a figure, the figure usually comes from acute stroke medicine. Gusev and colleagues reported 12 mg a day for moderate stroke and 18 mg a day for severe stroke, over courses of 5 and 10 days. The registered 1% nasal solution holds 500 µg per drop, and its label reaches 20,000 µg a day at the top.
Those are hospital figures for people in the first hours and days after an infarct, inside a window measured against the 4.5-hour thrombolysis clock. They describe a rescue setting. They were not generated in healthy adults studying for an exam.
We report what each published source administered on the Semax dosage page. That page reports. It does not instruct, and neither does this one.
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
Liu et al., British Journal of Pharmacology, 2025 — paper titleNote the species and the sex in that title. It is the most recent independent mechanism finding on Semax, and it is female mice with spinal cord injuries.
What you can verify before you buy
You cannot verify an effect in advance. You can verify the vial. That is the part of a Semax purchase that has documents behind it.
- A batch certificate of analysis matching the lot number on the vial. See how to read a COA.
- Storage conditions, since peptide degradation is silent. See storage temperature.
- Legal status where you live, covered in are peptides legal.
Semax on this site lists at $67.99 a vial, which works out near $6.80 per mg. Peptriva publishes a per-batch certificate of analysis for each lot, which is the one document that makes a Semax purchase checkable. For how the sellers compare on paperwork, see the vendor comparison.
Semax is a research compound. Russian approval of a nasal stroke product is not an approval of a research vial, and it is not a claim that anything will change for you.
Semax
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- The only published human before-and-after for Semax is a 2020 brain scan of 52 healthy adults.
- That study measured resting-state connectivity, reporting a right-amygdala change. It did not measure focus or memory.
- Zero Western randomized controlled trials of Semax sit in PubMed.
- The strongest evidence is rat stroke gene expression work, including a reported rebalancing of 1,171 genes in 24 hours.
- Dose figures quoted online, like 12 mg and 18 mg a day, come from acute stroke reports, not from healthy-user research.
- The verifiable part of a purchase is the batch certificate of analysis, not the outcome.
What we're watching
semax nootropic honest review what the research actually shows
Frequently asked questions
Are there real Semax before and after photos?
No. Semax is a nasal peptide studied for stroke and brain gene expression. It does not change skin, muscle or body weight, so there is nothing for a photograph to show. The only published human before-and-after is a brain scan.
How long does Semax take to work?
Users commonly describe something within 5 to 20 minutes of a nasal dose. That timing comes from self-reports, not from a controlled trial. In rats, the measured gene expression shift after experimental stroke was reported at 24 hours.
Does Semax improve focus or memory in healthy people?
No controlled human data supports that. The one human study, Panikratova and colleagues in 2020, scanned 52 healthy adults and reported connectivity changes. It did not publish a cognitive performance result that anyone can quote.
Is Semax FDA approved?
No. Russia approved a nasal formulation for acute ischemic stroke and some cognitive disorders. That is a Russian registration for a medicine. It says nothing about the status of a research vial sold in the US.
Why is almost all Semax research Russian?
The peptide was developed in Moscow at the Institute of Molecular Genetics, and the deepest lab work comes from the Kurchatov Institute. Italian groups have replicated the copper and amyloid chemistry. A 2025 British Journal of Pharmacology paper is one of the few non-Russian in vivo results.
What would a real Semax before and after look like?
A placebo-controlled trial in healthy adults, with a validated cognitive battery scored before and after, and blinding on both sides. That study has not been published in English in about 30 years of the compound's existence.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Semax deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Uncontrolled, unverified self-report. Nothing here is measured and nothing is controlled. The positive posts are dramatic. One r/Biohacking user says a retaken IQ test went from 133 to 147. An r/NooTopics user credits Semax with ending a depression, and discloses an 8% commission on the vendor named in the same post. The same threads carry their own dissent. An r/Biohackers user felt a focus boost on day one, then nothing across three weeks, including after raising his dose. Another r/NooTopics user asks why almost everything he reads about it is positive. A filmed self-experiment by Ryan Atkinson ends with "While Semax may have worked to some degree, it definitely isn't the magic brain booster people claim it to be." Routes are not consistent either. One poster switched from subcutaneous injection to nasal spray, and the video's author injected. And in 2024 the vendor who runs r/NooTopics told buyers to throw out a batch of Semax and Selank bottles he suspected of fungal contamination.
Where the community and the published record disagree. Semax's human record is thin and almost entirely Russian. A PubMed search filtered to clinical trials returns four records, all in patients: two on ischemic stroke, one on optic nerve disease, one on motor neuron disease. All four are Russian-language papers in Russian journals, the oldest from 1997. One placebo-controlled study in healthy adults does exist. Lebedeva and colleagues, writing in the Bulletin of Experimental Biology and Medicine in 2018, scanned 24 volunteers with resting-state fMRI and reported a difference in the topography of one brain network. It did not measure focus, memory or productivity, which is what every post here is claiming. The threads have also drifted off the tested molecule. PubMed returns no results at all for "N-acetyl semax" or "acetyl semax amidate", the modified form named in two of these posts.
“To put it in perspective, I retook an IQ test recently—my baseline from a previous test was 133, and I scored a 147.”
How Semax & Selank completely turned my ADHD symptoms around (and an unexpected 14-point IQ jump)
“Almost everything I read online about Semax Amidate seems super positive, just pure benefits.”
“On the first day, I felt a good boost in focus and productivity, but every day since then I haven’t felt any difference.”
“Please do not use them, throw them away ASAP and get a refund.”
Contamination in square Semax and Selank bottles - IMPORTANT!
“To be transparent, I am also getting 8% in commission for this.”
Not Placeboo , not HONEY MOON phase. I solved depression with this
“I test it across multiple work sessions, track my focus, run memory tests, and compare working with it versus without it.”
The Semax Experiment: Trying Russia's Most Controversial Nootropic
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Panikratova, Y. R., Lebedeva, I. S., Sokolov, O. Y., et al. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
- Filippenkov, I. B., Shpetko, Y. Y., Stavchansky, V. V., et al. (2024). ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke. Biomedicines, 12(12), 2830. https://doi.org/10.3390/biomedicines12122830
- Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., et al. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Molecular Biology (Moscow), 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
- Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., et al. (2021). Brain protein expression profile confirms the protective effect of the ACTHPGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
- Filippenkov, I. B., Remizova, J. A., Stavchansky, V. V., et al. (2023). Synthetic adrenocorticotropic peptides modulate the expression pattern of immune genes in rat brain following the early post-stroke period. Genes, 14(7), 1382. https://doi.org/10.3390/genes14071382
- Liu, R., Chen, Y., Huang, H., et al. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
- Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Y., et al. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
- Glazova, N. Y., Manchenko, D. M., Volodina, M. A., et al. (2020). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 86, 102114. https://doi.org/10.1016/j.npep.2020.102114
- Sciacca, M. F. M., Naletova, I., Giuffrida, M. L., & Attanasio, F. (2022). Semax, a synthetic regulatory peptide, affects copper-induced abeta aggregation and amyloid formation in artificial membrane models. ACS Chemical Neuroscience, 13(4), 486–496. https://doi.org/10.1021/acschemneuro.1c00707
- Tomasello, M. F., Di Rosa, M. C., Naletova, I., et al. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
- Svishcheva, M. V., Mishina, Y. S., Medvedeva, O. A., et al. (2021). Morphofunctional state of the large intestine in rats under conditions of restraint stress and administration of peptide ACTH-PGP (Semax). Bulletin of Experimental Biology and Medicine, 170(3), 384–388. https://doi.org/10.1007/s10517-021-05072-z
- Elagina, A. A., Lyashev, Y. D., Lyashev, A. Y., et al. (2020). Correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Bulletin of Experimental Biology and Medicine, 168(5), 618–620. https://doi.org/10.1007/s10517-020-04764-2
- Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., et al. (2023). Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects. Chemical Biology & Drug Design, 101(6), 1393–1405. https://doi.org/10.1111/cbdd.14221